CA3117429A1 - Anti-tim-3 antibodies - Google Patents

Anti-tim-3 antibodies Download PDF

Info

Publication number
CA3117429A1
CA3117429A1 CA3117429A CA3117429A CA3117429A1 CA 3117429 A1 CA3117429 A1 CA 3117429A1 CA 3117429 A CA3117429 A CA 3117429A CA 3117429 A CA3117429 A CA 3117429A CA 3117429 A1 CA3117429 A1 CA 3117429A1
Authority
CA
Canada
Prior art keywords
antibody
seq
tim
cell
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3117429A
Other languages
English (en)
French (fr)
Inventor
Dong Zhang
Xinyan Zhao
Qi AN
David NANNEMANN
Rinat ZAYNAGETDINOV
Vanita SOOD
Christel IFFLAND
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CA3117429A1 publication Critical patent/CA3117429A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3117429A 2018-11-01 2019-11-01 Anti-tim-3 antibodies Pending CA3117429A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862754383P 2018-11-01 2018-11-01
US62/754,383 2018-11-01
PCT/US2019/059555 WO2020093023A1 (en) 2018-11-01 2019-11-01 Anti-tim-3 antibodies

Publications (1)

Publication Number Publication Date
CA3117429A1 true CA3117429A1 (en) 2020-05-07

Family

ID=69159931

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3117429A Pending CA3117429A1 (en) 2018-11-01 2019-11-01 Anti-tim-3 antibodies

Country Status (8)

Country Link
US (1) US20220081480A1 (https=)
EP (1) EP3873611A1 (https=)
JP (1) JP2022505925A (https=)
CN (1) CN113272017A (https=)
AU (1) AU2019371457A1 (https=)
CA (1) CA3117429A1 (https=)
IL (1) IL282707A (https=)
WO (1) WO2020093023A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7214440B2 (ja) * 2018-11-01 2023-01-30 三菱重工エンジニアリング株式会社 検証処理装置、検証処理方法及びプログラム
EP4372006A4 (en) * 2021-07-16 2025-10-08 Brightpath Biotherapeutics Co Ltd ANTIBODY OR ANTIBODY DERIVATIVE TO TIM-3 ANTIGEN, AND USE THEREOF
WO2023040940A1 (zh) * 2021-09-15 2023-03-23 江苏恒瑞医药股份有限公司 Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
AU2023300419A1 (en) 2022-07-01 2025-01-02 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2025202222A1 (en) 2024-03-25 2025-10-02 Institut National de la Santé et de la Recherche Médicale Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells
WO2026059950A1 (en) * 2024-09-10 2026-03-19 Agilent Technologies, Inc. Anti-human tim3 antibodies for in vitro diagnostics

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
CA3253628A1 (en) 2010-03-05 2025-11-29 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
HUE045065T2 (hu) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
BR112016014952A2 (pt) 2014-02-10 2017-09-19 Merck Patent Gmbh Inibição direcionada de tgfbeta
KR20170075778A (ko) * 2014-10-27 2017-07-03 에이전시 포 사이언스, 테크놀로지 앤드 리서치 항-tim-3 항체
US20180153986A1 (en) * 2015-04-24 2018-06-07 The Brigham And Women's Hospital, Inc. Interactions between ceacam and tim family members
EP3878465A1 (en) * 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
PE20181326A1 (es) * 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
CN109757103B (zh) * 2016-07-14 2024-01-02 百时美施贵宝公司 针对tim3的抗体及其用途
JOP20190013A1 (ar) * 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)
MX2019005116A (es) * 2016-11-01 2019-11-12 Anaptysbio Inc Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3).
TWI665216B (zh) * 2016-12-29 2019-07-11 財團法人生物技術開發中心 抗人類tim-3抗體及其使用方法
WO2018129553A1 (en) * 2017-01-09 2018-07-12 Tesaro, Inc. Methods of treating cancer with anti-tim-3 antibodies
MY202480A (en) 2017-05-12 2024-04-30 Shanghai hengrui pharmaceutical co ltd Fusion protein containing tgf- receptor and medicinal uses thereof

Also Published As

Publication number Publication date
AU2019371457A1 (en) 2021-05-20
JP2022505925A (ja) 2022-01-14
IL282707A (en) 2021-06-30
EP3873611A1 (en) 2021-09-08
US20220081480A1 (en) 2022-03-17
WO2020093023A1 (en) 2020-05-07
CN113272017A (zh) 2021-08-17

Similar Documents

Publication Publication Date Title
CN112423845B (zh) 结合pd-l1和cd137的抗体分子
US20220081480A1 (en) Anti-tim-3 antibodies
EP3728316B1 (en) Fc binding fragments comprising a pd-l1 antigen-binding site
US20220073616A1 (en) Methods of administering anti-tim-3 antibodies
CN111356477B (zh) 双特异性抗体及其用途
AU2020363041B2 (en) Antibodies against the poliovirus receptor (PVR) and uses thereof
KR102608723B1 (ko) 항―ｐｄ－１ 항체 및 그의 용도
KR20200083598A (ko) 이뮤노글로불린-유사 전사체 3 (ilt3)에 대해 특이적인 항체 및 그의 용도
JP7689116B2 (ja) Ｐｄ１およびｖｅｇｆｒ２二重結合剤
WO2019184935A1 (zh) 抗cd27抗体、其抗原结合片段及其医药用途
WO2020058762A1 (en) Antibodies specific to ctla-4 and uses thereof
WO2020021061A1 (en) Humanized anti-pd-1 antibodies and uses thereof
WO2023164872A1 (en) Anti-cd39 antibodies and use thereof
KR20230158058A (ko) 시알산-결합 ig-유사 렉틴 15에 특이적인 항체 및 이의 용도
CN117377692A (zh) Tim-3-靶向抗体及其用途
HK40058527A (en) Anti-tim-3 antibodies
RU2826084C2 (ru) МОЛЕКУЛЫ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ PD-L1 и CD137
HK40059550A (en) Methods of administering anti-tim-3 antibodies
KR20250154601A (ko) Nkg2a와 pd-l1에 결합하는 작용제 및 이의 용도
KR20260013511A (ko) 암 치료를 위한 조합 요법
HK40088961A (zh) 抗tigit抗体
HK40037072A (en) Fc binding fragments comprising a pd-l1 antigen-binding site
HK40037072B (en) Fc binding fragments comprising a pd-l1 antigen-binding site

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231101

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250902

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251217